EPLAW PATENT BLOG

UK – Huawei & ZTE v Conversant Wireless Licensing

Posted: February 6th, 2019

(1) Huawei Technologies Co., Ltd (2) Huawei Technologies (UK) Co., Ltd (3) ZTE Corporation & (4) ZTE (UK) Limited v Conversant Wireless Licensing S.A.R.L. (30 January 2019, Court of Appeal, UK, Case Nos. A3/2018/1274 and A3/2018/1278) The UK Court of Appeal (“CA”) dismissed an appeal by Huawei and ZTE’s Chinese and UK companies against the […]

READ MORE

UK – Regen Lab v. Estar Medical et al.

Posted: February 6th, 2019

Regen Lab SA v (1) Estar Medical Limited, (2) Estar Technologies Limited, (3) Medira Limited, (4) Lavender Medical Limited, (5) Antoine Turzi, UK Patents Court, 18 January 2019, [2019] EWHC 63 (Pat) The Patents Court held Regen’s European Patent (UK) 2 073 862 lacked novelty over a non-confidential prior use, and notably rejected the Defendants’ […]

READ MORE

UK – Novartis v. Dr. Reddy’s

Posted: February 5th, 2019

Novartis Pharmaceuticals UK Limited, Novartis Pharma AG & Novartis International Pharmaceutical AG v Dr. Reddy’s Laboratories (UK) Limited, UK Patents Court, 15 January 2019, [2018] EWHC 92 (Pat) In a recent case before the UK Patents Court, in addition to considering an application for summary judgment to revoke the patent in suit for added matter, […]

READ MORE

NL – Anheuser-Busch Inbev v. Heineken / threshold for access to evidence

Posted: February 1st, 2019

Anheuser-Busch Inbev N.V. v. Heineken Supply Chain B.V. et al., Interlocutory Judge of the District Court of The Hague, The Netherlands, 1 February 2019, Case No. ECLI:NL:RBDHA:2019:853 Anheuser holds EP 2 152 486 B1 (hereafter: EP 486) for an “integrally blow-moulded bag-in-container comprising an inner layer and an outer layer comprising energy absorbing additives, preform […]

READ MORE

EPO – Exceptions to patentability – Essentially biological processes for the production of plants

Posted: January 31st, 2019

EPO, Technical Board of Appeal 3.3.04, decision of July 5, 2018 in case T 2435/13 – Clubroot resistant plants/SYNGENTA, by Dr. Rudolf Teschemacher, Bardehle Pagenberg After decision T 1063/18 of December 5, 2018, stating that Rule 28 (2) EPC as introduced in 2017 is in conflict with Article 53(b) EPC, (see post dated December 11, 2018, […]

READ MORE

NL – Koninklijke Douwe Egberts v. Belmoca

Posted: January 30th, 2019

Koninklijke Douwe Egberts B.V. v. Belmoca BVBA, Interlocutory Judge of the District Court of The Hague, The Netherlands, 28 December 2018, Case No. ECLI:NL:RBDHA:2018:15453 Nespresso compatible coffee capsules. Koninklijke Douwe Egberts (hereafter: KDE) accuses Belmoca of indirect infringement of EP 521 relating to ‘A beverage preparation system, a capsule and a method for forming a […]

READ MORE

NL – Sandoz v. Eli Lilly – Alimta® / pemetrexed

Posted: January 24th, 2019

Sandoz International GmbH v. Eli Lilli and Company, District Court The Hague, The Netherlands, 16 January 2019, Case no. ECLI:NL:RBDHA:2019:321 Lilly holds European patent 1 313 508 B1 (hereafter: EP 508), entitled ‘Combination containing an antifolate and methylmalonic acid lowering agent’. Sandoz in tries to have EP 508 revoked due to lack of inventive step. […]

READ MORE

News – Dutch AIPPI ‘Zeist’ symposium 2019

Posted: January 24th, 2019

The Dutch AIPPI ‘Zeist’ symposium shall take place on 13 March 2019 in Hotel Figi in Zeist. The programme and registration details will be announced here.

READ MORE

EPO – Disclosure of the invention – Novelty – Purity of a chemical substance as a distinguishing feature

Posted: January 21st, 2019

EPO, Technical Board of Appeal 3.3.02, decision of 9 November 2018 in case T 1085/13 – Amorphous Lercanidipine Hydrochloride/Recordati Since decision T 990/96, OJ EPO 1998, 489, it has been consistent case law of the Boards of Appeal of the EPO that a document disclosing a low molecular chemical compound and its manufacture makes this […]

READ MORE

NL – G.D. Searle v. Sandoz

Posted: January 17th, 2019

G.D. Searle LLC. v. Sandoz B.V., PI Judge District Court the Hague d.d. 8 January 2019, ECLI:NL:RBDHA:2019:72 Searle was the holder of European patent EP 0 810 209 B1 titled “Alpha – and beta-amino acid hydroxyethylamino sulphonamides useful as retroviral protease inhibitors”, which lapsed on 23 August 2013. The claims of this patent define a […]

READ MORE